MDR_Button Contact_Button News_Button  

 

CBT-1® Clinical Testing as MDR Modulator

Phase I
Phase I in patients failing first line therapy using concurrent Doxorubicin  at several dosage levels designed to determine maximum tolerable dose in combination with fixed dose of Doxorubicin and pharmacokinetic interaction.

Phase I with Paclitaxel in patients who had failed first line therapy, including Paclitaxel.  Two additional patients entered on separate arm to study pharmacokinetic interaction.

Phase I study in combination with Paclitaxel and Carboplatin in unresectable NSCLC.

Phase I study in combination with Paclitaxel and Doxorubicin in advanced unresectable breast cancer.

 

 
 
Column Header 1 Column Header 2 Column Header 3
CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
CBT-1®, taken orally as a pill, was developed to reverse multi-drug resistance in cancer cells and to become part of a Cancer Treatment Program that is administered before a cancer cell can become drug resistant.
(MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.

 

© CBA Pharma, Inc. 2014 All Rights Reserved Contact Us Privacy Statement Terms and Conditions